BCMA-CAR-T cells effectively reduce autoantibodies (e.g., anti-SSA/SSB in Sjögren’s syndrome) but induce hypogammaglobulinemia, which is manageable via intravenous immunoglobulin (IVIG) supplementation. This evidence concerns the gene TRIM21 and Sjogren syndrome.